The FY24 Transformative Breast Cancer Consortium Development Award is intended to provide successful applicants the time and resources needed to bring investigators and breast cancer advocates together to establish a consortium framework and conduct preliminary research to support application to a future, full Transformative Breast Cancer Consortium Award (pending availability of funds). This is a development award and is a separate mechanism from the full consortium award. Recipients of the FY24 Transformative Breast Cancer Consortium Development Award are expected to submit an application to compete for the full Transformative Breast Cancer Consortium Award anticipated to be offered in a future fiscal year(s). However, it is not necessary to receive a development award in order to apply for a full consortium award in the future. For FY24, investigators may be named as Consortium Director on an application submitted to either (but not both) of these mechanisms. Detailed information on the FY24 Transformative Breast Cancer Consortium Award is available under a separate program announcement (HT942524BCRPTBCCA).
The FY24 Transformative Breast Cancer Consortium Development Award provides support to:
• Develop the infrastructure of a multi-institutional research team inclusive of scientists, clinicians, and breast cancer advocates (e.g., building appropriate collaborations, outlining integration, research management, administrative management, and communication plans, and devising an intellectual property plan)
• Generate necessary preliminary data to serve as proof of concept or for project integration
• Acquire research resources
• Develop a framework of necessary statistical analyses
Deadlines:
• Pre-Application Deadline: Sep. 12, 2024
• Application Submission Deadline: Sep. 26, 2024
Considering the current breast cancer landscape and the BCRP’s mission, all FY24 BCRP Transformative Breast Cancer Consortium Development Award applications must address at least one of the following overarching challenges unless adequate justification for exception is provided.*
• Prevent breast cancer (primary prevention)
• Identify determinants of breast cancer initiation, risk, or susceptibility
• Distinguish deadly from non-deadly breast cancers
• Conquer the problems of overdiagnosis and overtreatment
• Identify what drives breast cancer growth; determine how to stop it
• Identify why some breast cancers become metastatic
• Determine why/how breast cancer cells lie dormant for years and then re-emerge; determine how to prevent lethal recurrence
• Revolutionize treatment regimens by replacing them with ones that are more effective, less toxic, and impact survival
• Eliminate the mortality associated with metastatic breast cancer
Independent investigators at all academic levels (or equivalent) are eligible to be named as the Consortium Director on an application.
Investigators named as Consortium Director on a pre-application or full application submitted under funding opportunity HT942524BCRPTBCCA are not eligible to be named as the Principal Investigator (PI) under the current funding opportunity.
Investigators named as PI on an application submitted under funding opportunity HT942524BCRPTBCCDA are not eligible to submit a pre-application or full application for the same consortium under the current funding opportunity.
An eligible PI, regardless of ethnicity, nationality, or citizenship status, must be employed by or affiliated with an eligible organization.
The anticipated direct costs budgeted for the entire period of performance for an FY24 BCRP Transformative Breast Cancer Consortium Development Award should not exceed $100,000. Refer to Section II.D.5, Funding Restrictions, for detailed funding information.